Revolution Medicines, Inc.
$42.66B- Market cap
- $44.32B
- Debt
- +$193.93M
- Cash
- −$1.85B
Capital structure 100% equity / 0% debt · EV / Revenue 3683.88x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RVMD stock price at premium vs BKR $206.77 current versus $0.12 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BKR's multiple
Implied fair value · at RVMD's multiple
Snapshot Sep 8, 2026, 3:47 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVMD FY 2023 (ended Dec 31, 2023) · BKR FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 3683.88x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
BKR carries the larger enterprise value at $69.83B against $42.66B; BKR trades on the lower EV / Revenue multiple (2.52x vs 3683.88x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Baker Hughes Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.11x
0.32x
Net debt / EBITDA
Leverage against operating earnings
3.85x
—
Cash and equivalents
Liquid reserves on the balance sheet
$1.85B
—
Total debt
Interest-bearing obligations outstanding
$193.93M
$6.09B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
HALLIBURTON CO
RVMD vs HAL
SCHLUMBERGER LIMITED/NV
RVMD vs SLB
NOV Inc.
RVMD vs NOV
TechnipFMC plc
RVMD vs FTI
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.